Dirk Schnapauff1, Federico Collettini2, Kerstin Hartwig2, Gero Wieners2, Sascha Chopra2, Bernd Hamm2, Bernhard Gebauer2. 1. Department of Radiology, Charité Medical School, Universitätsmedizin Berlin, Campus Virchow-Clinic, Berlin, Germany Department of Gastroenterolgy and Hepatology, Charité Medical School, Universitätsmedizin Berlin, Campus Virchow-Clinic, Berlin, Germany Department of Haematology and Oncology, Charité Medical School, Universitätsmedizin Berlin, Campus Virchow-Clinic, Berlin, Germany Department of General, Visceral and Transplant Surgery, Charité Medical School, Universitätsmedizin Berlin, Campus Virchow-Clinic, Berlin, Germany dirk.schnapauff@charite.de. 2. Department of Radiology, Charité Medical School, Universitätsmedizin Berlin, Campus Virchow-Clinic, Berlin, Germany Department of Gastroenterolgy and Hepatology, Charité Medical School, Universitätsmedizin Berlin, Campus Virchow-Clinic, Berlin, Germany Department of Haematology and Oncology, Charité Medical School, Universitätsmedizin Berlin, Campus Virchow-Clinic, Berlin, Germany Department of General, Visceral and Transplant Surgery, Charité Medical School, Universitätsmedizin Berlin, Campus Virchow-Clinic, Berlin, Germany.
Abstract
AIM: Prevalence of patients with unresectable recurrence of hepatocellular carcinoma (HCC) after previous resection is rising. The purpose of this study was to determine survival of patients undergoing computed tomography-guided brachytherapy (CT-HDRBT). PATIENTS AND METHODS: Altogether 19 patients with unresectable HCC recurrence were treated with CT-HDRBT at our Institution. Patients underwent single-fraction high-dose irradiation by an iridium-192 source after CT fluoroscopy-guided catheter placement. The median tumor-enclosing target dose was 20 Gy. RESULTS: The median follow-up was 33 months. According to the Kaplan-Meier method, median overall survival after CT-HDRBT was 50 months, and median survival after first hepatic resection was 87 months. The median duration of local tumor control was 32 months and time to disease progression was 20 months. There were no serious complications after CT-HDRBT and no treatment-related deaths. CONCLUSION: CT-HDRBT is a safe, potentially life prolonging technique in patients with recurrence of HCC who have few therapeutic options. Copyright
AIM: Prevalence of patients with unresectable recurrence of hepatocellular carcinoma (HCC) after previous resection is rising. The purpose of this study was to determine survival of patients undergoing computed tomography-guided brachytherapy (CT-HDRBT). PATIENTS AND METHODS: Altogether 19 patients with unresectable HCC recurrence were treated with CT-HDRBT at our Institution. Patients underwent single-fraction high-dose irradiation by an iridium-192 source after CT fluoroscopy-guided catheter placement. The median tumor-enclosing target dose was 20 Gy. RESULTS: The median follow-up was 33 months. According to the Kaplan-Meier method, median overall survival after CT-HDRBT was 50 months, and median survival after first hepatic resection was 87 months. The median duration of local tumor control was 32 months and time to disease progression was 20 months. There were no serious complications after CT-HDRBT and no treatment-related deaths. CONCLUSION: CT-HDRBT is a safe, potentially life prolonging technique in patients with recurrence of HCC who have few therapeutic options. Copyright
Authors: Felix Krenzien; Moritz Schmelzle; Benjamin Struecker; Nathanael Raschzok; Christian Benzing; Maximilian Jara; Marcus Bahra; Robert Öllinger; Igor M Sauer; Andreas Pascher; Johann Pratschke; Andreas Andreou Journal: J Gastrointest Surg Date: 2018-01-23 Impact factor: 3.452